We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Postmarketing surveillance vs phase III

JAMA. 1981;245(24):2485-2489. doi:10.1001/jama.1981.03310490007004.
Text Size: A A A
Published online


The time required to get a new drug onto the US market has virtually doubled in the past 15 years, and nothing short of a "radical" rearrangement of the approval process is going to reverse that trend.

That is the view of William M. Wardell, MD, director of the Center for the Study of Drug Development, University of Rochester (NY) Medical Center. Wardell is the originator of the controversial "drug lag" hypothesis that contends that the United States is lagging behind other developed countries in introducing therapeutic drugs into medical practice.

Speaking to a national conference on drug prescribing held at New York's Mount Sinai School of Medicine, Wardell said that one way around the "logjam" might be to eliminate phase III of the Investigational New Drug (IND) process—that which has to do with collection of large masses of long-term clinical data—and rely instead on improved and intensified postmarketing surveillance


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.